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David E. Newby, MD, Alasdair J. Gray, MBCHB, MDSEE PAGE 1404C oronary computed tomography angiography(CTA) has excellent diagnostic accuracy forthe detection and assessment of coronary
artery disease. Its strengths are numerous, but 2
features are particularly noteworthy in the context
of patients with suspected unstable coronary heart
disease. First, it has a very high negative predictive
value that means clinicians can conﬁdently exclude
coronary artery disease. This is particularly important
in the emergency department, where it can facilitate
the rapid discharge of patients from hospital. Second,
it can detect both obstructive and nonobstructive
coronary artery disease, something that noninvasive
stress testing cannot achieve as it relies on the
presence of ﬂow limiting disease. This is highly
relevant for patients with unstable coronary heart
disease because the dynamic ruptured plaque may
not consistently cause ﬂow limitation and therefore
pass undetected on formal stress testing. Indeed,
most patients who present with recurrent myocardial
infarction will have a normal stress test at discharge
from their index admission with an acute coronary
syndrome. On the other hand, the shortcomings
of coronary CTA include the absence of a functional
assessment of disease and the tendency to over-
estimate the severity of coronary artery disease,
especially in the presence of marked coronary calciﬁ-
cation. However, with the advent of modern dynamic
volume scanners, follow-on computed tomography
perfusion assessments could help to address such
deﬁciencies.*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
From the Department of Cardiology, Royal Inﬁrmary, and University of
Edinburgh/British Heart Foundation Centre for Cardiovascular Science,
Edinburgh, United Kingdom. Dr. Newby is a consultant for Toshiba
and was chief investigator for SCOT-HEART (Scottish COmputed
Tomography of the HEART Trial). Dr. Gray was chief investigator for
the RAPID-CTCA (Rapid Assessment of Potential Ischaemic Heart
Disease With CTCA) trial.There is currently no deﬁnitive evidence for
superiority of one diagnostic strategy over another, or
indeed that any speciﬁc test can inﬂuence clinical
outcomes in patients with suspected coronary heart
disease. Current guidelines provide empirical guid-
ance for selection of the most appropriate diagnostic
modality to assess patients with stable or unstable
coronary heart disease. Test selection in European
guidelines (1) is based on pre-test probabilities and
preferences based on local expertise and availability
of stress testing modalities. American guidelines (2)
reserve coronary CTA for patients who cannot un-
dergo stress imaging and provides an algorithm to
select a stress testing modality based on the patient’s
ability to exercise, the presence of previous coronary
revascularization, and the recording of a normalresting electrocardiogram. Historically, most of the
evidence for these imaging assessments has been
predicated on the demonstration of improved diag-
nostic performance, better risk stratiﬁcation, and
avoidance of unnecessary invasive coronary angiog-
raphy. This, in part, relates to the problem that an
imaging strategy can only inﬂuence clinical outcome
if it has demonstrable effects on downstream decision
making by providing a more accurate diagnosis that
results in the more appropriate selection of treat-
ments associated with a reduction in cardiovascular
events. Such outcome trials have not been conducted
for the established and accepted modalities of exer-
cise electrocardiography, stress echocardiography,
myocardial scintigraphy, or cardiac magnetic reso-
nance perfusion. The wide range of these existing
choices has also led many to question whether we
need yet another technique such as coronary CTA in
an already crowded diagnostic space. This issue has
then raised the bar for coronary CTA to prove its
worth in modern clinical practice.
In this issue of iJACC, Linde et al. (3) have pre-
sented the ﬁndings of the CATCH (CArdiac cT in the
treatment of acute CHest pain) trial of 600 patients
presenting with symptoms of potentially unstable
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This is an important and major addition to the spec-
trum of recent trials assessing the impact of coronary
CTA in patients with stable and those with unstable
coronary heart disease (Figure 1). The major strengths
of this study were that all patients underwent coro-
nary CTA (although analysis of coronary CTA was
prohibited in the control group until study comple-
tion), patient care pathways were transformed into
protocols, and follow-up was comprehensive and
robust. They report that coronary CTA was associated
with better selection of patients for invasive angiog-
raphy with a lower normal coronary angiogram rate
despite greater use of invasive angiography. Coronary
CTA led to the increased use of preventative therapies
and substantially more percutaneous coronary inter-
vention at the index assessment. Given the modest
sample size, the number of subsequent hard events
was small but again coronary CTA did appear to be
associated with improved outcomes. These ﬁndings
are consistent with those from the SCOT-HEART
(Scottish COmputed Tomography of the HEART
Trial) (4) and PROMISE (PROspective Multicenter
Imaging Study for Evaluation of Chest Pain) trials (5)
of more stable patients. Indeed, these trials also
showed that coronary CTA-assisted diagnosis led to
better use of invasive angiography, greater use of
preventative therapies and increased rates of coro-
nary revascularization. In addition, arguably all 3
trials showed that coronary CTA was associated with
reduced rates of subsequent myocardial infarction,FIGURE 1 Coronary CTA Trials in CHD
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Recent clinical trials of coronary computed tomography angiography (Calthough for the PROMISE trial, this was only
apparent at 12 months. Finally, all 3 trials demon-
strated that coronary CTA does not appear to affect
the rate of subsequent readmission to hospital with
chest pain. The potential reasons for this are com-
plex, but this is a consistent feature of coronary CTA
trials to date.
The CATCH trial evaluated low to intermediate
risk patient with unstable symptoms. Three previous
trials (6–8) evaluated low-risk patients (event rates
of <1%) and principally demonstrated that coronary
CTA led to more rapid discharge from the emergency
department and was more cost effective. The CATCH
trial addressed an apparently higher risk population
with more prolonged follow-up and went beyond
healthcare resource use to the more important clinical
endpoints with which patients and clinicians are
concerned. Knowing whether a patient has coronary
artery disease from anoninvasive coronary CTA clearly
led to better care and outcome. We cannot ascertain
from the CATCH trial which therapeutic intervention
led to the improvement in clinical outcomes, but given
the nature and pathophysiology of this unstable
patient group, antiplatelet therapy and coronary
revascularization seem the most likely candidates.
Where next with coronary CTA? The CATCH trial
has started to explore the utility of coronary CTA
in potentially unstable patients, with a focus on pa-
tient outcomes. However, what about intermediate-
to high-risk patients, such as those with suspected
acute coronary syndrome and elevated plasmaptomatic
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TA) across the spectrum of coronary heart disease (CHD).
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diagnostic changes on their electrocardiograms? With
the introduction of high-sensitivity troponin assays,
myocardial injury and type 2myocardial infarctionwill
become increasingly prevalent and may result in
misdiagnosis, additional unnecessary invasive test-
ing, or initiation of inappropriate therapies. For many
countries, there are substantial subgroups of these
patients who could be rapidly discharged from hospi-
tal, who are currently admitted to hospital for pro-
longed rule-out protocols. Use of coronary CTA in this
setting and patient groups is the subject of the ongoing
RAPID-CTCA (Rapid Assessment of Potential Ischae-
mic Heart DiseaseWith CTCA) trial (NCT02284191) that
has recently commenced recruitment and is due to
report in 2018. It will be interesting to see whether
similar changes in treatment and patient outcome will
be observed in this even higher risk group.
The CATCH trial has added to the increasing
consistency of the ﬁndings from major coronary CTAtrials that have now thrown down the gauntlet to
other established imaging modalities. Functional
testing still has a place and role as demonstrated by
the CATCH trial where further stress testing was
needed in a proportion of patients who had under-
gone coronary CTA. However, the shoe is now on the
other foot. Coronary CTA has demonstrated its ability
to be cost effective, to have beneﬁcial effects on
patient management, and to lead to superior down-
stream patient outcomes. The guideline committees
will now need to re-evaluate the priority and place of
coronary CTA which has had to prove its worth more
than any other imaging modality to date.
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